Equities Analysts Set Expectations for OBIO FY2026 Earnings

Orchestra BioMed logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate to a loss of $1.37 per share from a loss of $1.52, while maintaining a Buy rating and a $12 price target.
  • Analyst sentiment is broadly positive: seven analysts rate OBIO a Buy and one a Sell, giving it a consensus Moderate Buy rating and an average price target of $13.29.
  • In its latest quarter, Orchestra BioMed reported a loss of $0.30 per share, better than the $0.40 loss analysts expected; revenue of $0.09 million fell short of the $0.13 million forecast.
  • Interested in Orchestra BioMed? Here are five stocks we like better.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Research analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Orchestra BioMed in a report released on Friday, November 13th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($1.37) for the year, up from their prior estimate of ($1.52). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Orchestra BioMed's current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Orchestra BioMed's Q4 2026 earnings at ($0.36) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.32) EPS, Q4 2027 earnings at ($0.32) EPS and FY2027 earnings at ($1.29) EPS.

Several other equities research analysts also recently weighed in on OBIO. Wall Street Zen raised Orchestra BioMed from a "sell" rating to a "hold" rating in a research report on Saturday. Piper Sandler reiterated an "overweight" rating on shares of Orchestra BioMed in a report on Thursday, October 15th. Chardan Capital reissued a "buy" rating and set a $20.00 price target on shares of Orchestra BioMed in a research report on Friday, October 23rd. B. Riley Financial upped their price target on Orchestra BioMed from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. Finally, Weiss Ratings raised shares of Orchestra BioMed from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, September 10th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Orchestra BioMed currently has a consensus rating of "Moderate Buy" and an average target price of $13.29.

Read Our Latest Stock Analysis on OBIO

Orchestra BioMed Price Performance

NASDAQ:OBIO opened at $7.12 on Tuesday. The business's 50-day moving average is $5.90 and its two-hundred day moving average is $4.64. Orchestra BioMed has a 12 month low of $3.46 and a 12 month high of $7.45. The company has a debt-to-equity ratio of 4.58, a current ratio of 7.25 and a quick ratio of 8.24.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.10. Orchestra BioMed had a negative net margin of 182.50% and a negative return on equity of 186.93%. The firm had revenue of $0.09 million during the quarter, compared to analysts' expectations of $0.13 million.

Hedge Funds Weigh In On Orchestra BioMed

Several large investors have recently modified their holdings of OBIO. Flat Footed LLC bought a new position in Orchestra BioMed during the 2nd quarter worth approximately $1,084,670. Rice Hall James & Associates LLC acquired a new position in shares of Orchestra BioMed in the 2nd quarter worth approximately $1,830,000. BlackRock Inc. bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at approximately $10,832,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at approximately $2,771,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Orchestra BioMed during the 2nd quarter valued at approximately $372,000. Institutional investors own 53.20% of the company's stock.

Insider Activity at Orchestra BioMed

In other Orchestra BioMed news, insider Darren Sherman sold 15,000 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $5.74, for a total transaction of $86,100.00. Following the transaction, the insider directly owned 1,104,402 shares in the company, valued at $6,339,267.48. This represents a 1.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Eric S. Fain acquired 20,000 shares of the firm's stock in a transaction on Monday, November 9th. The shares were bought at an average cost of $5.00 per share, with a total value of $100,000.00. Following the completion of the acquisition, the director owned 119,630 shares in the company, valued at $598,150. This represents a 20.07% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 58,000 shares of company stock worth $288,560 and have sold 45,000 shares worth $255,600. Insiders own 7.50% of the company's stock.

About Orchestra BioMed

(Get Free Report)

Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices. The company's lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.

Featured Stories

Earnings History and Estimates for Orchestra BioMed (NASDAQ:OBIO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Orchestra BioMed Right Now?

Before you consider Orchestra BioMed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.

While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines